LivaNova PLC
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vladimir A. Makatsaria
- Full Time Employees
- 3,300
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 20 Eastbourne Terrace London GL United Kingdom W2 6LG
- IPO Date
- Oct 19, 2015
- CIK
- 0001639691
- Website
- livanova.com
- Similar Companies
- Business
- LivaNova PLC (Nasdaq: LIVN) develops and markets medical devices focused on cardiopulmonary surgery and neuromodulation therapies for neurological and psychiatric disorders. The company offers a comprehensive portfolio including the Essenz heart-lung machine platform and related perfusion systems, high-performance oxygenators for adult and pediatric patients, autotransfusion systems, cannulae, perfusion tubing disposables; and the VNS Therapy system providing vagus nerve stimulation for drug-resistant epilepsy, difficult-to-treat depression and obstructive sleep apnea, alongside the aura6000 system for proximal hypoglossal nerve stimulation. LivaNova operates globally in over 100 countries with manufacturing sites in Italy, the United States and Canada; it was formed in 2015 through the merger of Sorin SpA and Cyberonics Inc. and maintains headquarters in London, UK. Recent developments include raising full-year 2025 revenue growth guidance to 8.5%-9.5% constant currency following Q3 2025 results that showed 12.5% organic revenue growth driven by Essenz sales and cardiopulmonary consumables; unveiling a 2030 strategic roadmap targeting high-single-digit-plus revenue CAGR, adjusted operating margins in the high-twenties and an independent US commercial launch for obstructive sleep apnea therapy in 2027; securing CMS reimbursement enhancements effective January 2026 that boost hospital payments for VNS Therapy implants by approximately 48%; initiating Essenz commercial launch in China; appointing Lucile Blaise as Global Head of Commercialization for Obstructive Sleep Apnea and Donald Zurbay to the Board of Directors in late 2025; and presenting long-term real-world data at medical conferences demonstrating up to 95% median seizure reductions with VNS Therapy at 36 months alongside health economics benefits including reduced hospitalizations.
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE
Dynatronics (NASDAQ:DYNT) vs. LivaNova (NASDAQ:LIVN) Critical Review
LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova Q2 Earnings Call Highlights
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
LivaNova PLC (LIVN) Hits Fresh High: Is There Still Room to Run?
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Amundi Cuts Stock Position in LivaNova PLC $LIVN
Bank of New York Mellon Corp Sells 206,050 Shares of LivaNova PLC $LIVN
3 Medical Instrument Stocks Betting on GenAI to Ease Industry Hurdles
LivaNova PLC (LIVN) Hit a 52 Week High, Can the Run Continue?
LivaNova to Announce Second-Quarter 2026 Results
LivaNova Reports Improved OSA Outcomes With PolySync Programming
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
Jette Nygaard-Andersen Joins LivaNova Board as a New Director
LivaNova PLC (LIVN) Shareholder/Analyst Call Prepared Remarks Transcript
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
LivaNova Appoints Anne Liddy as Chief Legal Officer